Harry Scholes

Oct 3, 2023 | elifesciences.org | María Rodríguez-López |Nicola Bordin |Jon Lees |Harry Scholes

eLife assessment This important study combines extensive phenotyping of genome-wide deletion mutants and machine learning-based prediction to generate a large scale resource for understanding the functions of thousands of fission yeast protein-coding genes. This resource is supported by convincing phenotyping data and state-of-the-art bioinformatic analyses and will be of interest to many geneticists.

May 11, 2023 | jdsupra.com | Harry Scholes

In October 2022, we reported that Biogen was seeking a preliminary injunction in its BPCIA case brought in the District of Delaware against Sandoz relating to Sandoz’s proposed multiple sclerosis biosimilar of TYSABRI (natalizumab). The parties completed their briefing on Biogen’s motion in April, and Judge Williams has scheduled a hearing for May 17 at 1 pm EST. Stay tuned to Big Molecule Watch for further development on this BPCIA case. [View source.]

May 10, 2023 | lexblog.com | Harry Scholes

In October 2022, we reported that Biogen was seeking a preliminary injunction in its BPCIA case brought in the District of Delaware against Sandoz relating to Sandoz’s proposed multiple sclerosis biosimilar of TYSABRI (natalizumab). The parties completed their briefing on Biogen’s motion in April, and Judge Williams has scheduled a hearing for May 17 at 1 pm EST. Stay tuned to Big Molecule Watch for further development on this BPCIA case.

May 10, 2023 | bigmoleculewatch.com | Harry Scholes

Biogen, Sandoz In October 2022, we reported that Biogen was seeking a preliminary injunction in its BPCIA case brought in the District of Delaware against Sandoz relating to Sandoz’s proposed multiple sclerosis biosimilar of TYSABRI (natalizumab).